CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Assertio Holdings Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Assertio Holdings Inc
100 S. Saunders Road, Suite 300
Phone: (224) 419-7106p:224 419-7106 LAKE FOREST, IL  60045  United States Ticker: ASRTASRT

Business Summary
Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-YesYes--

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board Peter D.Staple 72 5/19/2020 11/1/2003
Interim Chief Executive Officer, Director Heather L.Mason 63 1/2/2024 2/18/2019
Chief Financial Officer, Senior Vice President, Chief Accounting Officer AjayPatel 39 11/8/2023 3/11/2021
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
DEPOMED, INC.
Talon Therapeutics Inc Suite 200, 400 Oyster Point Blvd SOUTH SAN FRANCISCO CA United States
Allos Therapeutics, Inc. 11080 CirclePoint Road Westminster CO United States
Spectrum Pharmaceuticals, Inc. Pilot House - Lewis Wharf Boston MA United States

Business Names
Business Name
Alligator IP, LLC
Allos Therapeutics, Inc.
ASRT
19 additional Business Names available in full report.

General Information
Number of Employees: 53 (As of 12/31/2023)
Outstanding Shares: 94,995,823 (As of 3/5/2024)
Shareholders: 264
Stock Exchange: NASD
Federal Tax Id: 850598378
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024